Uncategorized
Myeloma Patients Europe (MPE) will hold a webinar to review the most recent updates on the approved COVID-19 vaccines in Europe and how they affect myeloma and AL amyloidosis patients. Continue reading
As part of the CARAMBA consortium, Myeloma Patients Europe (MPE) has developed an information sheet to explain the main goals and characteristics of the CARAMBA clinical trial investigating SLAMF7 chimeric antigen receptor T-cell (CAR-T) therapy. This publication discusses some potential CAR-T side effects and considerations for patients and caregivers. This information sheet has been previously published on our website in English and is now available in four additional languages: French, Italian, Spanish and German. Continue reading
Location: European Union or United Kingdom / home based
Contract: Full-time (part time also possible)
Location: European Union or United Kingdom / home based
Contract: Full-time (part time also possible) Continue reading
Location: Scotland / home based (approx. 10 travel days per year)
Contract: 40 hours per week / permanent
Salary: £25,000 – £27,000 depending on experience
This Research Assistant post supports the research function of Myeloma Patients Europe (MPE). There are two main elements to the job – supporting communication and dissemination of SISAQOL-IMI and to assist with generating patient centred evidence as part of MPE’s newly established Evidence Generation Unit (EGU). The following tasks and core responsibilities are non-exhaustive and subject to change depending on needs of the organisation.
Location: European Union or United Kingdom / home based (approx. 15 travel days per year)
Contract: Full-time (part time also possible) / permanent
Salary: 40.000 EUR/year GROSS
Myeloma Patients Europe (MPE) has put together an advice sheet for our members and myeloma patients on coronavirus (Covid-19). This advice has been reviewed by our scientific advisors and will be continually updated to reflect the latest information.
Dr Faith Davies, NYU Langone Hospital, New York, USA, explains in this video the pre-clinical myeloma updates presented in the American Society of Hematology (ASH) Annual Meeting 2019 and why are those important to patients. Continue reading
ASH 2019, Orlando – A number of early-phase studies were presented yesterday during the 61st American Society of Hematology (ASH) Annual Meeting spotlight the rapid advances being made in cellular immunotherapy for blood cancers. Researchers will present the results of early-phase studies of emerging “second-generation” cellular immunotherapy products that strive to overcome the limitations of existing products. Continue reading
It is with great sadness that we share that our friend, colleague and Board member Lisa Kotschi passed away in the night of the 21st November 2019. Continue reading